Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04625660 · ClinicalTrials.gov registry record · NA
Detour2 Continued Access Study
A NA study of Peripheral Artery Diseases, sponsored by Endologix.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 3
- Study locations
NCT04625660: Completed NA study of Peripheral Artery Diseases, sponsored by Endologix.
NCT04625660 is a NA study of Peripheral Artery Diseases that has completed, run by Endologix. The registered enrollment target is 11 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04625660, a NA study of Peripheral Artery Diseases, has completed, sponsored by Endologix.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 3
- Study locations
Study Summary
Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.
Primary Outcome
Freedom from a major adverse event (MAE) at 30 days post-procedure defined as any occurrence of the following events: Death, Clinically-Driven Target Lesion Revascularization (CD-TLR), Major Amputation of the Treated Limb, Symptomatic Deep Vein Thrombosis (DVT), or Pulmonary Embolism, or procedure-related bleeding requiring any transfusion of packed red blood cells or surgery.
Conditions Studied
Interventions
- DEVICE PQ Bypass System
Study Locations (3)
Connecticut
- The Vascular Experts - Old Saybrook
Illinois
- AMITA Medical Group - Elk Grove Village
Virginia
- Sentara Norfolk - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-04-07 |
| Est. Completion | 2024-05-14 |
| Phase | NA |
What the finished NCT04625660 record still lists
NCT04625660 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Peripheral Artery Diseases appearing as the primary indexed condition, and to 1 intervention - of which PQ Bypass System is the first listed.
NCT04625660 reports a single indexed study location in Connecticut, Illinois, Virginia.
Frequently Asked Questions
What is clinical trial NCT04625660 about?
NCT04625660 is a clinical study titled "Detour2 Continued Access Study". Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.
What is the current status of trial NCT04625660?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2021-04-07. Estimated completion is 2024-05-14.
What conditions does trial NCT04625660 study?
This clinical trial studies the following conditions: Peripheral Artery Diseases.
What interventions are being tested in trial NCT04625660?
The interventions under investigation include: PQ Bypass System (DEVICE).
Who is sponsoring clinical trial NCT04625660?
This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04625660 being conducted?
This trial has 3 study locations across Connecticut, Illinois, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04625660's enrollment target sits among peer trials
11 1927th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI